Absolute Antibody Launches FleXpress

Absolute Antibody, a provider of recombinant antibody products and services, has launched its FleXpress high-throughput recombinant antibody production service, which offers customers the flexibility to rapidly express a large number of antibodies at 80 ml scale. All production occurs in the company’s ISO-certified antibody manufacturing facility in Northeast England, which recently expanded to increase production capacity and meet the growing demand for recombinant antibody technology.
 
The high-throughput recombinant antibody production service is ideal for early-stage pharmaceutical researchers conducting pilot studies on a group of therapeutic antibody candidates, as well as reagent companies with a monoclonal antibody portfolio interested in converting their collection from hybridomas to recombinant production. Recombinant antibodies, long the standard in pharmaceutical development, are becoming increasingly popular for research and diagnostic applications due to their superior batch-to-batch reproducibility, antibody engineering options, and guaranteed long-term supply.
 
The antibody production service utilizes Absolute Antibody’s HEXpress antibody expression platform, a serum-free, mammalian transient expression system that offers a faster, more affordable alternative to stable CHO cell line generation. The proprietary system produces high-quality recombinant antibodies in any species, isotype or format, including multispecifics and fragments, with high purity and low endotoxin levels. 
 
The FleXpress production line can recombinantly manufacture hundreds of different antibodies per week at 80 ml scale, allowing Absolute Antibody to quickly respond to customer needs for high-throughput small-to-medium-scale recombinant antibody production. It joins two other production lines at the company’s antibody manufacturing facility, which also offers the option to scale to multi-gram quantities in a matter of weeks. 
 
“Absolute Antibody specializes in recombinant antibody technology, and we’ve developed a robust and reliable platform for high-throughput antibody production at relatively small scales,” said Catherine Bladen, chief operations officer, Absolute Antibody. “Our new production line gives our customers the flexibility to rapidly and cost-effectively test recombinant versions of many different antibodies using our proven recombinant expression technology.”
 
In 2019, Absolute Antibody produced thousands of different recombinant antibodies, making 120 grams of protein in total, for customers across pharmaceuticals, biotechnology, research reagents, diagnostics, and academia. Since its founding in 2012, the company has also used its production platform to build a unique recombinant antibody catalog consisting of nearly 5,000 antibodies, all benefitting from antibody engineering technology. The FleXpress production service enables customers to utilize this same technology for their own recombinant antibody projects.